NR 546 Final Exam Prep Document | 2026/2027 Edition | 200
Verified Questions - 180 Questions with Answers
NR 546 Final Exam 2026-180 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified Solutions |
Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document is meticulously designed for advanced pharmacology
nurse practitioner students at Chamberlain University. It contains 200 verified questions and answers
that mirror the content and format of the NR 546 final exam. Each question is accompanied by a
detailed rationale to reinforce key pharmacological concepts and clinical applications. This resource is
essential for achieving a top score on the final exam.
Key Features:
Neuropharmacology and psychopharmacology
Pharmacokinetics and pharmacodynamics
Drug interactions and adverse effects
Prescribing for special populations
Evidence-based treatment guidelines
Clinical case studies and application
Updates for 2026:
- Updated to reflect 2026-2027 academic year guidelines
- Revised to include latest FDA-approved medications
- Enhanced rationales with current clinical evidence
- Added new questions on emerging therapies
- Aligned with Chamberlain University curriculum updates
Abstract:
This exam preparation document is a scholarly compilation of 200 practice questions tailored for the NR 546
Advanced Pharmacology for Nurse Practitioners final exam at Chamberlain University. The content spans core
areas of neuropharmacology, including antidepressants, antipsychotics, anxiolytics, and mood stabilizers, with
emphasis on mechanisms of action, therapeutic uses, and adverse effect profiles. Each question is followed by a
verified answer and a detailed rationale that explains the correct choice and why distractors are incorrect,
facilitating deep learning and retention. The document also integrates clinical case scenarios to enhance
application skills, ensuring that students are prepared for both exam success and real-world prescribing. Updated
for the 2026/2027 academic year, it reflects the latest evidence-based guidelines and pharmacological
advancements. This resource is indispensable for nurse practitioner students seeking a comprehensive review and
a high level of competency in advanced pharmacology.
Keywords:
NR 546, Advanced Pharmacology, Nurse Practitioner, Final Exam, Practice Questions, Verified Answers,
Chamberlain University, 2026-2027
Answer Format:
Each question is presented in multiple-choice format with four options. The correct answer is clearly indicated,
followed by a comprehensive rationale explaining the pharmacological principles, clinical reasoning, and why the
other options are incorrect. This format reinforces understanding and aids in exam preparation.
Compliance Checklist:
Aligned with Chamberlain University NR 546 course objectives
Updated to 2026-2027 academic year standards
Page 1
, Includes 200 verified questions with rationales
Covers all major topics in advanced pharmacology
Suitable for self-assessment and exam review
Instant PDF download for convenient access
Content Area Overview:
Content Area Questions Key Topics Weight
Neuropharmacology 1-40 Antidepressants, Antipsychotics, 20%
Anxiolytics, Mood Stabilizers
Pharmacokinetics and 41-80 Absorption, Distribution, Metabolism, 20%
Pharmacodynamics Excretion, Receptor Binding
Drug Interactions and Adverse 81-120 Cytochrome P450, Drug-Drug Interactions, 20%
Effects Side Effect Profiles, Toxicity
Special Populations 121-160 Pediatrics, Geriatrics, Pregnancy, 20%
Renal/Hepatic Impairment
Clinical Application and Case 161-200 Prescribing Scenarios, Treatment 20%
Studies Algorithms, Patient Education, Monitoring
Page 2
,Q1. A patient with type 2 diabetes and chronic kidney disease (eGFR 30 mL/min) is
prescribed metformin. Which pharmacokinetic property necessitates dose adjustment
in this patient?
A. High protein binding leading to altered free drug concentration
B. Renal excretion of the active drug and its metabolites
C. Extensive hepatic metabolism via CYP3A4
D. Long half-life requiring loading dose
Correct Answer: B. Renal excretion of the active drug and its metabolites
Rationale: Metformin is primarily excreted unchanged by the kidneys. In renal
impairment, accumulation increases the risk of lactic acidosis. Thus, dose adjustment or
discontinuation is required based on eGFR. Other options do not reflect metformin's
primary elimination pathway.
Why Wrong:
A - Metformin is not highly protein bound; protein binding is not the primary concern
in renal impairment.
C - Metformin does not undergo significant hepatic metabolism via CYP3A4.
D - Metformin does not have a long half-life requiring a loading dose; its half-life is
relatively short.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 54
Q2. Which of the following best explains the mechanism by which sulfonylureas lower
blood glucose in type 2 diabetes?
A. Activation of AMP-kinase in the liver
B. Inhibition of SGLT2 in the proximal tubule
C. Blockade of ATP-sensitive potassium channels on pancreatic beta cells
D. Agonism at GLP-1 receptors
Correct Answer: C. Blockade of ATP-sensitive potassium channels on pancreatic beta
cells
Rationale: Sulfonylureas bind to the sulfonylurea receptor (SUR1) on pancreatic beta
cells, closing ATP-sensitive potassium channels, leading to depolarization and insulin
release. This is their primary mechanism. Other options describe mechanisms of
metformin, SGLT2 inhibitors, and GLP-1 receptor agonists.
Why Wrong:
A - AMP-kinase activation is the mechanism of metformin, not sulfonylureas.
B - SGLT2 inhibition is the mechanism of gliflozins, not sulfonylureas.
D - GLP-1 receptor agonism is the mechanism of GLP-1 receptor agonists, not
sulfonylureas.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 55
Page 3
, Q3. A patient on warfarin requires an antibiotic. Which agent is most likely to
increase the INR and elevate bleeding risk?
A. Ciprofloxacin
B. Azithromycin
C. Penicillin VK
D. Cephalexin
Correct Answer: A. Ciprofloxacin
Rationale: Ciprofloxacin inhibits CYP1A2 and CYP3A4, which metabolize the less active
(S)-warfarin? Actually, the (S)-warfarin is metabolized by CYP2C9. Ciprofloxacin inhibits
CYP1A2, which metabolizes (R)-warfarin, but it also has some effect on CYP2C9.
Clinically, fluoroquinolones are known to potentiate warfarin's effect. Azithromycin has
minimal interaction; penicillins and cephalosporins have minimal effect unless they alter
gut flora.
Why Wrong:
B - Azithromycin has minimal interaction with warfarin.
C - Penicillin VK has minimal interaction with warfarin.
D - Cephalexin has minimal interaction with warfarin.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 39
Q4. A patient prescribed an ACE inhibitor develops a dry cough. What is the most
likely mechanism?
A. Increased bradykinin levels
B. Histamine release from mast cells
C. Direct irritation of the bronchial mucosa
D. Beta-2 receptor blockade
Correct Answer: A. Increased bradykinin levels
Rationale: ACE inhibitors prevent the breakdown of bradykinin, which accumulates and
irritates the airways, causing a dry cough. This is not an allergic reaction. Histamine
release, direct irritation, and beta-2 blockade are not mechanisms of ACE
inhibitor-induced cough.
Why Wrong:
B - Histamine release is not the primary mechanism; it is an anaphylactoid reaction,
not typical cough.
C - Direct irritation is not the mechanism; the cough is due to bradykinin
accumulation.
D - Beta-2 blockade is not a property of ACE inhibitors.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 23
Page 4
Verified Questions - 180 Questions with Answers
NR 546 Final Exam 2026-180 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified Solutions |
Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document is meticulously designed for advanced pharmacology
nurse practitioner students at Chamberlain University. It contains 200 verified questions and answers
that mirror the content and format of the NR 546 final exam. Each question is accompanied by a
detailed rationale to reinforce key pharmacological concepts and clinical applications. This resource is
essential for achieving a top score on the final exam.
Key Features:
Neuropharmacology and psychopharmacology
Pharmacokinetics and pharmacodynamics
Drug interactions and adverse effects
Prescribing for special populations
Evidence-based treatment guidelines
Clinical case studies and application
Updates for 2026:
- Updated to reflect 2026-2027 academic year guidelines
- Revised to include latest FDA-approved medications
- Enhanced rationales with current clinical evidence
- Added new questions on emerging therapies
- Aligned with Chamberlain University curriculum updates
Abstract:
This exam preparation document is a scholarly compilation of 200 practice questions tailored for the NR 546
Advanced Pharmacology for Nurse Practitioners final exam at Chamberlain University. The content spans core
areas of neuropharmacology, including antidepressants, antipsychotics, anxiolytics, and mood stabilizers, with
emphasis on mechanisms of action, therapeutic uses, and adverse effect profiles. Each question is followed by a
verified answer and a detailed rationale that explains the correct choice and why distractors are incorrect,
facilitating deep learning and retention. The document also integrates clinical case scenarios to enhance
application skills, ensuring that students are prepared for both exam success and real-world prescribing. Updated
for the 2026/2027 academic year, it reflects the latest evidence-based guidelines and pharmacological
advancements. This resource is indispensable for nurse practitioner students seeking a comprehensive review and
a high level of competency in advanced pharmacology.
Keywords:
NR 546, Advanced Pharmacology, Nurse Practitioner, Final Exam, Practice Questions, Verified Answers,
Chamberlain University, 2026-2027
Answer Format:
Each question is presented in multiple-choice format with four options. The correct answer is clearly indicated,
followed by a comprehensive rationale explaining the pharmacological principles, clinical reasoning, and why the
other options are incorrect. This format reinforces understanding and aids in exam preparation.
Compliance Checklist:
Aligned with Chamberlain University NR 546 course objectives
Updated to 2026-2027 academic year standards
Page 1
, Includes 200 verified questions with rationales
Covers all major topics in advanced pharmacology
Suitable for self-assessment and exam review
Instant PDF download for convenient access
Content Area Overview:
Content Area Questions Key Topics Weight
Neuropharmacology 1-40 Antidepressants, Antipsychotics, 20%
Anxiolytics, Mood Stabilizers
Pharmacokinetics and 41-80 Absorption, Distribution, Metabolism, 20%
Pharmacodynamics Excretion, Receptor Binding
Drug Interactions and Adverse 81-120 Cytochrome P450, Drug-Drug Interactions, 20%
Effects Side Effect Profiles, Toxicity
Special Populations 121-160 Pediatrics, Geriatrics, Pregnancy, 20%
Renal/Hepatic Impairment
Clinical Application and Case 161-200 Prescribing Scenarios, Treatment 20%
Studies Algorithms, Patient Education, Monitoring
Page 2
,Q1. A patient with type 2 diabetes and chronic kidney disease (eGFR 30 mL/min) is
prescribed metformin. Which pharmacokinetic property necessitates dose adjustment
in this patient?
A. High protein binding leading to altered free drug concentration
B. Renal excretion of the active drug and its metabolites
C. Extensive hepatic metabolism via CYP3A4
D. Long half-life requiring loading dose
Correct Answer: B. Renal excretion of the active drug and its metabolites
Rationale: Metformin is primarily excreted unchanged by the kidneys. In renal
impairment, accumulation increases the risk of lactic acidosis. Thus, dose adjustment or
discontinuation is required based on eGFR. Other options do not reflect metformin's
primary elimination pathway.
Why Wrong:
A - Metformin is not highly protein bound; protein binding is not the primary concern
in renal impairment.
C - Metformin does not undergo significant hepatic metabolism via CYP3A4.
D - Metformin does not have a long half-life requiring a loading dose; its half-life is
relatively short.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 54
Q2. Which of the following best explains the mechanism by which sulfonylureas lower
blood glucose in type 2 diabetes?
A. Activation of AMP-kinase in the liver
B. Inhibition of SGLT2 in the proximal tubule
C. Blockade of ATP-sensitive potassium channels on pancreatic beta cells
D. Agonism at GLP-1 receptors
Correct Answer: C. Blockade of ATP-sensitive potassium channels on pancreatic beta
cells
Rationale: Sulfonylureas bind to the sulfonylurea receptor (SUR1) on pancreatic beta
cells, closing ATP-sensitive potassium channels, leading to depolarization and insulin
release. This is their primary mechanism. Other options describe mechanisms of
metformin, SGLT2 inhibitors, and GLP-1 receptor agonists.
Why Wrong:
A - AMP-kinase activation is the mechanism of metformin, not sulfonylureas.
B - SGLT2 inhibition is the mechanism of gliflozins, not sulfonylureas.
D - GLP-1 receptor agonism is the mechanism of GLP-1 receptor agonists, not
sulfonylureas.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 55
Page 3
, Q3. A patient on warfarin requires an antibiotic. Which agent is most likely to
increase the INR and elevate bleeding risk?
A. Ciprofloxacin
B. Azithromycin
C. Penicillin VK
D. Cephalexin
Correct Answer: A. Ciprofloxacin
Rationale: Ciprofloxacin inhibits CYP1A2 and CYP3A4, which metabolize the less active
(S)-warfarin? Actually, the (S)-warfarin is metabolized by CYP2C9. Ciprofloxacin inhibits
CYP1A2, which metabolizes (R)-warfarin, but it also has some effect on CYP2C9.
Clinically, fluoroquinolones are known to potentiate warfarin's effect. Azithromycin has
minimal interaction; penicillins and cephalosporins have minimal effect unless they alter
gut flora.
Why Wrong:
B - Azithromycin has minimal interaction with warfarin.
C - Penicillin VK has minimal interaction with warfarin.
D - Cephalexin has minimal interaction with warfarin.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 39
Q4. A patient prescribed an ACE inhibitor develops a dry cough. What is the most
likely mechanism?
A. Increased bradykinin levels
B. Histamine release from mast cells
C. Direct irritation of the bronchial mucosa
D. Beta-2 receptor blockade
Correct Answer: A. Increased bradykinin levels
Rationale: ACE inhibitors prevent the breakdown of bradykinin, which accumulates and
irritates the airways, causing a dry cough. This is not an allergic reaction. Histamine
release, direct irritation, and beta-2 blockade are not mechanisms of ACE
inhibitor-induced cough.
Why Wrong:
B - Histamine release is not the primary mechanism; it is an anaphylactoid reaction,
not typical cough.
C - Direct irritation is not the mechanism; the cough is due to bradykinin
accumulation.
D - Beta-2 blockade is not a property of ACE inhibitors.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 23
Page 4
